Industry
Cellular Sciences, inc.
Total Trials
6
Recruiting
0
Active
0
Completed
5
Success Rate
83.3%-3% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
Failure Rate
16.7%
1 terminated/withdrawn out of 6 trials
Success Rate
83.3%
-3.2% vs industry average
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
60%
3 of 5 completed trials have results
Key Signals
3 with results
Enrollment Performance
Analytics
Phase 2
3(50.0%)
Phase 1
2(33.3%)
Phase 3
1(16.7%)
6Total
Phase 2(3)
Phase 1(2)
Phase 3(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (6)
Showing 6 of 6 trials
NCT06037408Phase 3Completed
The Effect of N115 on Coughing in IPF Patients
Role: lead
NCT04824365Phase 2Completed
Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection
Role: lead
NCT04871815Phase 2Completed
Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.
Role: lead
NCT00308243Phase 1Completed
Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
Role: collaborator
NCT00332215Phase 1Terminated
A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
Role: collaborator
NCT00262613Phase 2Completed
Sodium Pyruvate Therapy in COPD Patients
Role: collaborator
All 6 trials loaded